About: PF-610355

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer. It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically-mediated adverse events. Its in vivo duration on action confirmed its potential for once-daily use in humans.

Property	Value
dbo:abstract	PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer. It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically-mediated adverse events. Its in vivo duration on action confirmed its potential for once-daily use in humans. The investigation and development of PF-610355 were discontinued in 2011, likely for strategic and regulatory reasons. (en)
dbo:casNumber	862541-45-5
dbo:chEMBL	1240967
dbo:fdaUniiCode	ZH5SMU97AJ
dbo:pubchem	11505444
dbo:thumbnail	wiki-commons:Special:FilePath/PF-610355.svg?width=300
dbo:wikiPageID	50101970 (xsd:integer)
dbo:wikiPageLength	4927 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	984403781 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Pfizer dbr:In_vivo dbc:Abandoned_drugs dbc:Phenols dbr:Chronic_obstructive_pulmonary_disease dbr:Crystallinity dbr:Zwitterion dbr:Long-acting_beta-adrenoceptor_agonist dbr:Sulfonamide dbr:Agonist dbr:Asthma dbc:Long-acting_beta2-adrenergic_agonists dbr:Adverse_event dbr:Pharmacokinetics
dbp:atcPrefix	None (en)
dbp:c	34 (xsd:integer)
dbp:casNumber	862541 (xsd:integer)
dbp:chembl	1240967 (xsd:integer)
dbp:chemspiderid	9680243 (xsd:integer)
dbp:h	39 (xsd:integer)
dbp:iupacName	N-[methyl]-2-[3-phenyl]acetamide (en)
dbp:legalStatus	Development terminated (en)
dbp:n	3 (xsd:integer)
dbp:o	6 (xsd:integer)
dbp:pubchem	11505444 (xsd:integer)
dbp:routesOfAdministration	Inhalation (en)
dbp:s	1 (xsd:integer)
dbp:unii	ZH5SMU97AJ (en)
dbp:watchedfields	changed (en)
dbp:width	230 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Respiratory-system-drug-stub dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Asthma_and_copd_rx dbt:Adrenergic_agonists
dcterms:subject	dbc:Abandoned_drugs dbc:Phenols dbc:Long-acting_beta2-adrenergic_agonists
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer. It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically-mediated adverse events. Its in vivo duration on action confirmed its potential for once-daily use in humans. (en)
rdfs:label	PF-610355 (en)
owl:sameAs	yago-res:PF-610355 wikidata:PF-610355 https://global.dbpedia.org/id/2MktF dbr:PF-610355
prov:wasDerivedFrom	wikipedia-en:PF-610355?oldid=984403781&ns=0
foaf:depiction	wiki-commons:Special:FilePath/PF-610355.svg
foaf:isPrimaryTopicOf	wikipedia-en:PF-610355
is dbo:wikiPageWikiLink of	dbr:Long-acting_beta-adrenoceptor_agonist
is foaf:primaryTopic of	wikipedia-en:PF-610355